Clinical trials: Primary Neoplasm
CLDN18.2 Positive, Primary Gastric Adenocarcinoma
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a prospective, randomized, open, multicenter phase II clinical trial. It plans to enroll 70 participants with locally advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC) who are assessed as…
- Conditions
- CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07483567
- Testing
- IBI343,sintilimab,oxaliplatin,S-1, sintilimab,oxaliplatin,S-1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Moderate to Severe Primary Dysmenorrhea
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)
The purpose of this study is to assess the etonogestrel (ENG) + 17β-estradiol (E2) vaginal ring's efficacy compared to a placebo vaginal ring in the treatment of dysmenorrhea at Treatment Cycle 2.
- Trial name
- NCT02668783
- Testing
- Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring, Ibuprofen
- Volunteers
- 25 people
- Sponsor
- Organon and Co
Primary Immunodeficiency
CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01…
- Trial name
- NCT03907241
- Testing
- Octanorm 16.5%
- Where
- 7 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Octapharma
Headache Disorders, Primary, Migraine With Aura
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headaches are a common medical problem that physicians frequently encounter in their practice. One of key findings of The Atlas of Headache Disorders prepared by World Health Organization (WHO) is: headache disorders, including…
- Conditions
- Headache Disorders, Primary, Migraine With Aura, Migraine Without Aura, Tension-Type Headache
- Trial name
- PRESTO (NCT02115269)
- Where
- 30 sites in Kazakhstan, Ukraine
- Volunteers
- 759 people
- Sponsor
- Abbott
Recurrent Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
To compare the efficacy of Transarterial Chemoembolization (TACE) to CyberKnife stereotactic body radiotherapy in the treatment of patients with locally recurrent hepatocellular carcinoma (HCC) after TACE.
- Trial name
- NCT01318200
- Testing
- Transarterial Chemoembolization, CyberKnife SBRT
- Where
- United States
- Sponsor
- Accuray Incorporated
Hypotension, Ischemia
Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty
The purpose of this study is to determine whether Hemospan is superior to Voluven for preventing hypotensive episodes during the perioperative period (from induction of spinal anesthesia until 6 hours after skin closure), and for…
- Trial name
- NCT00421200
- Testing
- Hemospan (MP4OX), Voluven (HES 130/0.4)
- Where
- 18 sites in Belgium, Czechia and 4 more
- Volunteers
- 375 people
- Sponsor
- Sangart
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Cancer of Unknown Primary Site
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have…
- Trial name
- CUPISCO (NCT03498521)
- Testing
- Alectinib, Vismodegib, Ipatasertib
- Where
- 125 sites in Australia, Austria and 31 more
- Volunteers
- 529 people
- Sponsor
- Hoffmann-La Roche
Osteoarthritis, Post-traumatic Arthritis
ATTUNE Single-Use Instrumentation vs. ATTUNE Reusable Instrumentation in Primary Total Knee Arthroplasty
This post-marketing investigation will evaluate the mechanical axis alignment achieved with the ATTUNE Single-Use Instrumentation (SUI) as compared to the mechanical axis alignment achieved with the ATTUNE Reusable…
- Trial name
- SOLO (NCT02574312)
- Testing
- ATTUNE TKA with ATTUNE RUI, ATTUNE TKA with ATTUNE SUI
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 88 people
- Sponsor
- DePuy Orthopaedics
Hypercholesterolemia
Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)
This is a multicenter, randomized, double blind; active-controlled parallel groups study enrolling subjects with primary hypercholesterolemia.
- Trial name
- NCT00650819
- Testing
- Ezetimibe + Simvastatin, Simvastatin, Ezetimibe
- Volunteers
- 240 people
- Sponsor
- Organon and Co
Migraine
Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fasted conditions.
- Trial name
- NCT01161667
- Testing
- naratriptan hydrochloride
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Primary Sclerosing Cholangitis
Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)
The objectives of this qualitative study are to elicit concepts about symptoms that are important to patients with primary sclerosing cholangitis (PSC), as well as the key impacts of symptoms on patients' day-to-day functioning.
- Trial name
- NCT02247934
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences
Tuberous Sclerosis Complex, Focal Cortical Dysplasia
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type…
- Trial name
- NCT06392009
- Testing
- Radiprodil
- Where
- 18 sites in Australia, Belgium and 6 more
- Volunteers
- 30 people
- Sponsor
- GRIN Therapeutics, Inc.
Myelofibrosis, Primary Myelofibrosis
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving…
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551053
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 17 more
- Volunteers
- 177 people
- Sponsor
- Incyte Corporation
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
- Trial name
- NCT01879319
- Testing
- Evolocumab AMD, Evolocumab AI/pen
- Where
- 27 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen
Multiple Sclerosis
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
This was a retrospective cohort study using the electronic medical record (EMR) database from Cleveland Clinic. The data was analyzed at start of ofatumumab (OMB) therapy (baseline, defined as 6 months prior to OMB initiation)…
- Trial name
- NCT06737419
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
This was an open label, randomized study comparing the efficacy and safety of randomized 2:1 Ruxolitinib tablets versus best-available therapy, as selected by the investigator.
- Trial name
- NCT00934544
- Testing
- Ruxolitinib, Best Available Therapy (BAT)
- Where
- 61 sites in Austria, Belgium and 7 more
- Volunteers
- 219 people
- Sponsor
- Novartis Pharmaceuticals
Hyperuricemia
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
This is a randomized, open-label, parallel-controlled, multicenter clinical trial in primary hyperuricemia patients with or without gout.
- Trial name
- NCT05504083
- Testing
- D-0120, Benzbromarone
- Where
- 24 sites in China
- Volunteers
- 121 people
- Sponsor
- InventisBio Co., Ltd
Hereditary Angioedema (HAE)
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to…
- Trial name
- CHAPTER-3 (NCT06669754)
- Testing
- Deucrictibant
- Where
- 56 sites in United States, Argentina and 22 more
- Volunteers
- 81 people
- Sponsor
- Pharvaris Netherlands B.V.
Hypertension, MTHFR 677 TT Genotype
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype.
- Trial name
- CSPPT2-TT (NCT04974151)
- Testing
- Amlodipine besylate, Amlodipine besylate And Folic Acid, 5-methyltetrahydrofolate (5-MTHF)
- Where
- 20 sites in China
- Volunteers
- 24,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd